| NMIBC | Non-muscle-invasive bladder cancer |
| MIBC | Muscle-invasive bladder cancer |
| BCG | Bacillus Calmette–Guérin |
| BRS (BRS1–3) | BCG Response Subtypes |
| CISTO | Comparison of Intravesical Therapy and Surgery as Treatment Options |
| TURBT | Transurethral resection of the bladder tumor |
| EORTC | European Organization for Research and Treatment of Cancer |
| CUETO | Spanish Urological Club for Oncological Treatment |
| CIS | Carcinoma in situ |
| LVI | Lymphovascular invasion |
| RFS | Recurrence-free survival |
| PFS | Progression-free survival |
| GI | Genome instability (subtype) |
| AA-like | Aristolochic acid-associated (subtype) |
| EMT | Epithelial-to-mesenchymal transition |
| Tregs | Regulatory T cells |
| MDSCs | Myeloid-derived suppressor cells |
| IDO1 | Indoleamine 2,3-dioxygenase |
| lncRNAs | Long non-coding RNAs |
| RC | Radical cystectomy |
| BST | Bladder-sparing therapy |